Concepedia

Author

Anna Turkina

National Medical Research Center for HematologyORCID

Also Known As

A G Turkina, A G. Turkina, A I Udovichenko, A Turkina, A. G. Tukrina, A. G. Turkina, A. Turkina, A.G. Turkina, Anna G Turkina, Anna G. Turkina

367

Publications

5K

Citations

25

H-Index

55

Concepts

All Affiliations

National Medical Research Center for HematologyFederal Almazov North-West Medical Research CentreThe University of Texas MD Anderson Cancer CenterRussian Research Institute of Hematology and TransfusiologyNovartis (Switzerland)
AT

About

Anna Turkina is an author at National Medical Research Center for Hematology specializing in medicine, oncology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

1.1K

2

Health Sciences

11

12

535

3

Public Health

2

2

276

4

Engineering

1

1

16

5

Nursing

1

1

26

Anna Turkina

×

56

Publications

3.1K

Citations

25

H-Index

YearCitations

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Jörge E. Cortes, Hagop M. Kantarjian, Tim H. Brümmendorf,

Blood

2011

457

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Delphine Réa, Michael J. Mauro, Carla Boquimpani,

Blood

2021

319

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Verena Hoffmann, Michele Baccarani, Joerg Hasford,

Leukemia

2015

250

Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia

Susan O’Brien, Charles Cunningham, A. Golenkov,

Journal of Clinical Oncology

2005

190

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jörge E. Cortes, Jane F. Apperley, Elza Lomaia,

Blood

2021

185

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase

François-Xavier Mahon, Carla Boquimpani, Dong‐Wook Kim,

Annals of Internal Medicine

2018

127

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Andreas Hochhaus, Delphine Réa, Carla Boquimpani,

Leukemia

2023

126

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up

Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Dong‐Wook Kim,

American Journal of Hematology

2014

116

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

Verena Hoffmann, Michele Baccarani, Joerg Hasford,

Leukemia

2016

103

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

Markus Pfirrmann, Richard E. Clark, Witold Prejzner,

Leukemia

2020

93

Page 1